AlphAIalphai — Financial news for AI agents
gurufocus.comAUG 272 min read$RVMD

RVMD Maintained by Oppenheimer -- Price Target Raised to $260

Oppenheimer maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised its price target from $230 to $260. The biotech company has a $46.8B market cap but faces profitability and growth concerns, with a GF Score of 25/100. Insiders have sold $54.5M in shares over the past three months.

Original reporting
gurufocus.com
Published Aug 27, 2026, 3:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 6:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$RVMD
Bullish
medium confidence
Mentioned
$RVMD · $OPY
Relevance
7/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$RVMDBullishMed
01

Why it matters

Target raise may attract short-term buying, but fundamentals remain weak.

02

Market read

Analyst upgrade could prompt modest price movement in RVMD.

03

What to watch

Potential clinical trial risks and cash burn not addressed in the rating update.

Relevance 7/10Novelty 6/10Timing: today

Background

Revolution Medicines is a clinical-stage oncology company with recent analyst coverage.

Company-level read

Ticker impact

$RVMDBullishMedium confidence
Context

Oppenheimer raised RVMD's price target to $260, indicating fresh analyst optimism.

Expected impact

Potential modest price gain if market reacts to the upgrade.

Evidence & confidence

Target increase reflects confidence but insider sell-off and high valuation suggest limited upside.

Market effects

Sector

May influence biotech sector sentiment as analysts adjust targets.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

High insider selling and elevated P/S ratio could signal overvaluation despite target raise.

Key entities

  • Company
    Revolution Medicines Inc

    Biotech firm developing RAS-targeted therapies.

  • Analyst Firm
    Oppenheimer

    Provided the rating update and new price target.

Read at source← All news

Related articles

AUG 28
$RVMDHighAI 8/10

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines (RVMD) received FDA approval for its pancreatic cancer drug, Rasonque, just weeks after filing. The drug showed significant efficacy in trials, leading to a 178% stock increase year-to-date. Analysts project peak sales of $11.5 billion, with potential for broader cancer treatment applications.

fool.com2 min
AUG 28
$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

rttnews.com4 min
AUG 28
$OPYHigh

Why is Oppenheimer Holdings stock gaining over 2% today?

Oppenheimer Holdings stock rose 2.7% in pre-market trading to $123.25, surpassing its 52-week high, as the company distributed a $0.20 per share dividend. This follows strong Q2 2026 earnings, with revenue up 21.9% YoY to $454.9M and adjusted EPS at $4.27. Client assets under management reached a record $59.4B. The stock's technical breakout and positive fundamentals drove the gain, independent of broader market trends.

investing.com1 min
AUG 26
$RVMDHighAI 9/10

FDA approves drug poised to transform care for pancreatic cancer

The FDA approved Revolution Medicines' drug daraxonrasib (Rasonque) for advanced pancreatic cancer. In trials, patients lived a median of 13 months vs. 7 with chemotherapy. The drug targets KRAS, a protein driving many cancers. Revolution Medicines did not disclose pricing, but analysts expect it to cost hundreds of thousands annually. The approval follows a fast-tracked review and positive clinical trial data.

boston.com2 min
AUG 26
$RVMDHighAI 9/10

FDA approves life-extending pancreatic cancer drug Rasonque

FDA approved Revolution Medicines' pancreatic cancer drug Rasonque on Aug. 26. Clinical trials showed median life expectancy nearly doubled for patients. The drug is priced at $39,800 for a 30-day supply, with potential co-pay assistance. Revolution's stock has risen 166% this year, closing at $211.89 on approval day.

yahoo.com2 min
AUG 26
$RVMDHighAI 9/10

Revolution Medicines Wins FDA Pancreatic Cancer Drug Approval

Revolution Medicines (RVMD) received FDA approval for daraxonrasib (Rasonque) for metastatic pancreatic cancer, 6.5 months ahead of schedule. The drug showed a median overall survival of 13.2 months vs. 6.7 months for chemotherapy. RVMD shares closed at $212.81, up 0.68%. The company reported widening losses in Q2 2026, with a net loss of $644.4m. Analysts have an average price target of $222.89.

financial-news.co.uk2 min